logo
#

Latest news with #Lisbon

Ryanair demands urgent intervention as passengers face long delays and missed flights at major airport
Ryanair demands urgent intervention as passengers face long delays and missed flights at major airport

Daily Mail​

time18 hours ago

  • Business
  • Daily Mail​

Ryanair demands urgent intervention as passengers face long delays and missed flights at major airport

Ryanair has demanded the Portuguese government 'urgently fix' staffing issues at airports across the country that have led to almost 300 passengers miss their flights. Europe's largest budget airline said the those that have managed to fly, including many travelling with young children, were being left to endure delays of up to two and a half hours. The problems are 'completely unacceptable', said Ryanair. Ongoing border control staff shortages at Faro, Lisbon, and Porto airports have been blamed for the issue, which are leading to 'excessive' queues. The carrier said that 'urgent action' is needed, especially during the peak morning period. It claims that during the two-week period from 26 May to 9 June, 270 passengers departing the affected airports missed their flights. Neal McMahon, Ryanair COO, criticised airport operator ANA Aeroportos de Portugal for the chaos. He blamed it for failing to ensure that 'adequate staff are in place to manage border control'. He added: 'This is not good enough, and the problem will only worsen as we go further into the summer season and traffic numbers increase.' Earlier this month, Portugal's minister of infrastructure, Miguel Pinto Luz, attempted to reassure tourists, promising that issues around border control would be 'resolved within two weeks', according to The Mirror. Ivaylo Danailov, CEO of airline compensation specialists SkyRefund, is warning that those caught up in the problems could be in line for some money under European Union rules. 'When severe border control delays at Portugal's major airports cause missed flights, airline passengers may be entitled to compensation or rerouting under EU Regulation 261/2004, especially if the airline could have mitigated the disruption. However, he added that it's a 'grey area'. 'Airlines are not required to pay compensation if a delay or missed flight was due to factors outside their control, such as political instability, extreme weather, or airport staff strikes (which includes border control issues not managed by the airline). 'But, if the airline could have reasonably foreseen the disruption, for example, repeated border delays and failed to act, it has been known for courts to have sometimes ruled in favour of the passenger. 'For instance, they may argue the airline should have allowed more time for security and border procedures or co-ordinated better. 'Either way passengers have a right to care and rebooking.' Vinci Airports, which operates the three airports under its ANA Aeroportos de Portugal subsidiary, has been contacted for comment. British tourists have begun using e-gates at Faro Airport after a deal was struck with the UK government. Since Brexit, Britons arriving at EU airports have generally been forced to queue for manned desks to have their passports stamped, rather than use automated gates with facial recognition technology – leading to long waits, particularly during peak periods. The Portuguese airport has started the rollout of e-gate access to British arrivals after Prime Minister Sir Keir Starmer confirmed an agreement with EU leaders last month. It hopes the deal will smooth over 'legal barriers to e-gates use for UK nationals', once a new stamp-free biometric Entry/Exit System (EES) launches in October.

Pan American Airways Is Back, But It's Not What It Seems
Pan American Airways Is Back, But It's Not What It Seems

Bloomberg

time21 hours ago

  • Bloomberg

Pan American Airways Is Back, But It's Not What It Seems

A small gaggle of former Pan American World Airways flight attendants stood by a window in Terminal 7 at John F. Kennedy International Airport, craning their necks and holding up phones. There were a few audible gasps and a soft cry of 'Oh gosh, there it is' as the plane came into view. Several of the women teared up as the jet finally slid past the window, its fin bearing the unmistakable cobalt-blue meatball of the Pan Am logo. The former flight attendants—and several dozen fellow passengers—were at JFK on Tuesday to board the plane, a chartered Boeing 757 that's being billed as a 'Pan Am journey by private air.' Over 12 days the plane will travel from New York to Bermuda and then on to Lisbon, Marseille, London, and Shannon, Ireland, before returning to New York City. The plane itself, which has capacity for 50 passengers, features fully reclinable lie-back seats, personal devices from which to stream entertainment options, as well as an open bar and chef-prepared meals served by attendants dressed in full Pan Am regalia. The trip cost $59,950 per person for double occupancy, $5,600 more for single occupancy.

Renting with apps like Airbnb and Vrbo used to be so great. What happened?
Renting with apps like Airbnb and Vrbo used to be so great. What happened?

Washington Post

time21 hours ago

  • Washington Post

Renting with apps like Airbnb and Vrbo used to be so great. What happened?

I'm writing to you from a home rental in France where we had to rent our sheets and towels. No joke, 15 euros a day. When we leave, we have to bring them back — folded. And then it hit me: Were we given the last renter's dirty linens? We rented an Airbnb in Lisbon a couple of years ago. It was on the fifth floor of an apartment building and promised 180-degree views of the city below. But when we arrived late that night, there were no views of the city. There were only views of scaffolding out of every window. Disappointed, we threw our bags down and sat on the bed. It collapsed.

Viktor Gyokeres ‘tells family which club he expects to join in huge transfer decision for Man Utd and Arsenal'
Viktor Gyokeres ‘tells family which club he expects to join in huge transfer decision for Man Utd and Arsenal'

The Sun

time21 hours ago

  • Sport
  • The Sun

Viktor Gyokeres ‘tells family which club he expects to join in huge transfer decision for Man Utd and Arsenal'

VIKTOR GYOKERES has told his family where he expects to play next season, according to reports. The Sporting Lisbon striker is being looked at by both Arsenal and Manchester United this summer. 1 Gyokeres, 27, is certain to leave the Portuguese giants although they are "playing hardball" by demanding an £80m fee. talkSPORT reporter Alex Crook said: "I had a message 24 hours or so ago suggesting that Viktor Gyokeres has told friends and family he expects to join Arsenal. "We know that Manchester United are interested in signing him as well - obviously there is that pre-existing relationship with Ruben Amorim. "But Arsenal can offer Champions League football, maybe can offer a tilt at the title next season. "Arsenal are juggling both him and Benjamin Sesko, they've opened talks with Leipzig as well. "But at the moment, I would say Gyokeres looks the more likely." The Swede is said to be considering going on strike to force his Sporting exit. Gyokeres is furious as he believes the club have broken a promise that he would be sold for £50million with a further £8million in add-ons. JOIN SUN VEGAS: GET £50 BONUS That agreement was supposedly made with former chief Hugo Viana. But since his departure to Manchester City, club president Frederico Varandas is handling the transfer. He has slammed Gyokeres last week, saying: "Sporting will not accept blackmail and insults – you should know me better by now. 'One thing is certain, we will not accept £50m plus £8m. As of now, Sporting has not received any bids for Gyokeres. "It was agreed that Sporting would not demand the release clause at the end of the season, especially because he was going to be 27. "We knew about Viktor's dream of going to a club where he could fight for the Champions League and we have common sense. "We guaranteed that we would not demand £85m. Sporting has common sense, it keeps its word." Sesko, 22, is also on Arsenal's radar and reports in Germany say they have agreed personal terms with him. Inside Arsenal's frustrating striker transfer saga By Jordan Davies ARSENAL'S never-ending hunt for a world-class striker is in turmoil as deals for Benjamin Sesko and Viktor Gyokeres stall. The Gunners were confident of doing their business quickly this summer after months of preparation by boss Mikel Arteta and new sporting director Andrea Berta. But inflated asking prices and broken gentlemen's agreements have derailed those plans and left Arsenal frustrated. Sesko believed he would be allowed to leave RB Leipzig for around £60million, while SunSport understands Gyokeres was told £59m would be enough to seal his own exit. But those price-tags have gone up, leaving Arsenal debating whether they represent value for money. While the players' camps are also growing restless, knowing the Gunners can only sign one of them. So what next? Will Arsenal keep waiting in the hope of fees eventually going down? Or turn to other targets, like Frankfurt's Hugo Ekitike? Whatever they decide, with pre-season looming and the fixtures already out, Arteta will be desperate for them to move quickly to avoid another nearly season.

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010's Efficacy
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010's Efficacy

Yahoo

timea day ago

  • Business
  • Yahoo

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010's Efficacy

Presented at EACR 2025, promising results show the impact of Brenus Pharma and InSphero's collaboration in advancing translational immunotherapy through scalable 3D tumor models. LISBON, Portugal, June 19, 2025--(BUSINESS WIRE)--Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus' lead candidate for colorectal cancer. Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010's therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed by monocyte-derived dendritic cells (mMo-DCs), activating CD8+ T cells. These T cells induced apoptosis in both 2D and 3D colorectal cancer models and released anti-tumor cytokines (IFNγ and Granzyme B). These data reinforce the therapeutic potential of STC-1010. "This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates." Benoit Pinteur, CSO of Brenus Pharma. "We are proud to support Brenus with our cryopreserved 3D tumor models. This work illustrates how advanced in vitro systems can bring immunotherapies closer to clinical reality." Jan Lichtenberg, CEO of InSphero. About Brenus Pharma Brenus Pharma unlocks the potential of immuno-oncology by generating first-in-class immunotherapies that initiate a multi-specific in vivo immune response against tumors. Their proprietary "off-the-shelf" Stimulated-tumor-Ghost-Cells (SGC) platform mimics patients' tumor cells and makes them visible to the immune system to anticipate, target, and destroy these cells as they appear. Brenus aims to shift the oncology paradigm by making patients active participants in their treatment. About InSphero InSphero sets the standard for in vitro drug discovery and safety testing with innovative 3D cell-based technology and comprehensive preclinical research solutions. Its reliable, scalable and reproducible suite of 3D InSight™ Platforms for Liver Safety, Liver Disease, Islet Biology, and Oncology & Immunology are used by the top pharmaceutical companies worldwide. Learn more at View source version on Contacts contact@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store